Obinutuzumab Mouse, Clone: 18H8, GenScript™

Mouse Monoclonal Antibody

Supplier:  Genscript Corporation A0194540

Catalog No. 50-212-0667

Description

Reconstitute the lyophilized antibody with deionized water (or equivalent) to a final concentration of 0.5 mg/mL. Obinutuzumab is a humanized anti-CD20 monoclonal antibody, originated by GlycArt Biotechnology AG and developed by Roche as a cancer treatment. It was approved under the trade name Gazyva by the US FDA in 2013, and as Gazyvaro by the EMA in Europe, for the treatment of chronic lymphocytic leukemia in combination with chemotherapy in treatment-naive patients, and as a second line treatment for follicular lymphoma. Obinutuzumab is a fully humanized monoclonal antibody that binds to an epitope on CD20 that partially overlaps with the epitope recognized by rituximab. Obinutuzumab binds to CD20 on B cells and causes these cells to be destroyed by engaging the adaptive immune system, directly activating intracellular apoptosis pathways, and activating the complement system.

Obinutuzumab Monoclonal antibody specifically detects Obinutuzumab in Chemical samples. It is validated for ELISA

Specifications

• Antigen: Obinutuzumab
• Classification: Monoclonal
• Conjugate: Unconjugated
• Gene Alias: Gazyva; Gazyvaro
• Immunogen: Obinutuzumab
• Quantity: 40 μg
• Primary or Secondary: Primary
• Product Type: Antibody
• Isotype: IgG1 κ

• Applications: ELISA
• Clone: 18H8
• Formulation: PBS with 0.02% sodium azide; pH 7.4
• Host Species: Mouse
• Purification Method: Protein A
• Regulatory Status: RUO
• Content And Storage: -20°C or -80°C if preferred
• Form: Lyophilized
• Target Molecule: Chemical